Plasma cholesteryl ester transfer, but not cholesterol esterification, is related to lipoprotein-associated phospholipase A2: Possible contribution to an atherogenic lipoprotein profile

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 4, 2011, Pages 1077-1084

  Dullaart, Robin P F ^a   Constantinides, Alexander ^a   Perton, Frank G ^a,b   Van Leeuwen, Jeroen J J ^b   Van Pelt, Joost L ^b   De Vries, Rindert ^a   Van Tol, Arie ^a,c  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL ESTER TRANSFER PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; SULFONYLUREA;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL ESTERIFICATION; COLORIMETRY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; ENZYME ACTIVITY; FEMALE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN ANALYSIS; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; ATHEROSCLEROSIS; CASE-CONTROL STUDIES; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL ESTERS; DIABETES MELLITUS, TYPE 2; ESTERIFICATION; FEMALE; HUMANS; LINEAR MODELS; LIPOPROTEINS; MALE; METABOLIC SYNDROME X; METABOLOME; MIDDLE AGED; TRIGLYCERIDES;

EID: 79953846129     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-2139     Document Type: Article

References (48)

1. Caslake MJ, Packard CJ 2005 Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke. Nat Clin Pract Cardiovasc Med 2:529-535 (Pubitemid 41670344)
2. Wilensky RL, Macphee CH 2009 Lipoprotein-associated phospholipase A(2) and atherosclerosis. Curr Opin Lipidol 20:415-420
3. Tellis CC, Tselepis AD 2009 The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta 1791:327-338
4. Kujiraoka T, Iwasaki T, Ishihara M, Ito M, Nagano M, Kawaguchi A, Takahashi S, Ishi J, TsujiM,Egashira T, Stepanova IP, Miller NE, Hattori H 2003 Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus. J Lipid Res 44:2006-2014 (Pubitemid 37356674)
5. Iwase M, Sonoki K, Sasaki N, Ohdo S, Higuchi S, Hattori H, IidaM 2008 Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: Relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment. Atherosclerosis 196:931-936
6. Sonoki K, Iwase M, Sasaki N, Ohdo S, Higuchi S, Matsuyama N, Iida M 2009 Relations of lysophosphatidylcholine in low-density lipoprotein with serum lipoprotein-associated phospholipase A2, paraoxonase and homocysteine thiolactonase activities in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 86:117-123
7. Lp-PLA(2) Studies Collaboration, Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, Ballantyne C, Cannon CP, Criqui M, Cushman M, Hofman A, Packard C, Thompson SG, Collins R, Danesh J 2010 Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: Collaborative analysis of 32 prospective studies. Lancet 375:1536-1544
8. Tall AR 1993 Plasma cholesteryl ester transfer protein. J Lipid Res 34:1255-1274 (Pubitemid 23230305)
9. Borggreve SE, De Vries R, Dullaart RP 2003 Alterations in highdensity lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: Role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 33:1051-1069 (Pubitemid 38019139)
10. Dullaart RP, Dallinga-ThieGM,Wolffenbuttel BH, van TolA2007 CETP inhibition in cardiovascular risk management: A critical appraisal. Eur J Clin Invest 37:90-98 (Pubitemid 46066487)
11. Chapman MJ, Le Goff W, Guerin M, Kontush A 2010 Cholesteryl ester transfer protein: At the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J 31:149-164
12. Kappelle PJ, van Tol A, Wolffenbuttel BH, DullaartRP14 July 2010 Cholesteryl ester transfer protein inhibition in cardiovascular risk management: Ongoing trials will end the confusion. Cardiovasc Ther doi: 10.1111/j.1755-5922.2010.00201.x
13. Krishna R, Anderson MS, Bergman AJ, Jin B, Fallon M, Cote J, Rosko K, Chavez-Eng C, Lutz R, Bloomfield DM, Gutierrez M, Doherty J, Bieberdorf F, Chodakewitz J, Gottesdiener KM, Wagner JA 2007 Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: Two doubleblind, randomised placebo-controlled phase I studies. Lancet 370: 1907-1914 (Pubitemid 350192656)
14. Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J; dal- OUTCOMES Committees and Investigators 2009 Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 158:896-901.e3
15. Dullaart RP, Groener JE, Erkelens DW 1987 Effect of the composition of very low and low density lipoproteins on the rate of cholesteryl ester transfer from high density lipoproteins in man, studied in vitro. Eur J Clin Invest 17:241-248
16. Lagrost L 1994 Regulation of cholesteryl ester transfer protein (CETP) activity: Review of in vitro and in vivo studies. Biochim Biophys Acta 1215:209-236
17. de Vries R, Perton FG, Dallinga-Thie GM, van Roon AM, Wolffenbuttel BH, van Tol A, Dullaart RP 2005 Plasma cholesteryl ester transfer is a determinant of intima-media thickness in type 2 diabetic and nondiabetic subjects: Role of CETP and triglycerides. Diabetes 54:3554-3559 (Pubitemid 43334349)
18. Nishida HI, Arai H, Nishida T 1993 Cholesterol ester transfer mediated by lipid transfer protein as influenced by changes in the charge characteristics of plasma lipoproteins. J Biol Chem 268: 16352-16360 (Pubitemid 23229938)
19. Lagrost L, Florentin E, Guyard-Dangremont V, Athias A, Gandjini H, Lallemant C, Gambert P 1995 Evidence for nonesterified fatty acids as modulators of neutral lipid transfers in normolipidemic human plasma. Arterioscler Thromb Vasc Biol 15:1388-1396
20. Benítez S, Sánchez-Quesada JL, Ribas V, Jorba O, Blanco-Vaca F, Gonzá lez-Sastre F, Ordóñez-Llanos J 2003 Platelet-activating factor acetylhydrolase is mainly associated with electronegative low-density lipoprotein subfraction. Circulation 108:92-96 (Pubitemid 36859026)
21. Gaubatz JW, Gillard BK, Massey JB, Hoogeveen RC, Huang M, Lloyd EE, Raya JL, Yang CY, Pownall HJ 2007 Dynamics of dense electronegative low density lipoproteins and their preferential association with lipoprotein phospholipase A(2). J Lipid Res 48:348-357 (Pubitemid 46220601)
22. Dullaart RP, Groen AK, Dallinga-Thie GM, de Vries R, Sluiter WJ, van Tol A 2008 Fibroblast cholesterol efflux to plasma from metabolic syndrome subjects is not defective despite low HDL cholesterol. Eur J Endocrinol 158:53-60 (Pubitemid 351211040)
23. Riemens SC, van Tol A, Scheek LM, Dullaart RP 2001 Plasma cholesteryl ester transfer and hepatic lipase activity are related to highdensity lipoprotein cholesterol in association with insulin resistance in type 2 diabetic and non-diabetic subjects. Scand J Clin Lab Invest 61:1-9 (Pubitemid 32240867)
24. Fielding CJ, Fielding PE 1981 Regulation of human plasma lecithin: Cholesterol acyltransferase activity by lipoprotein acceptor cholesteryl ester content. J Biol Chem 256:2102-2104 (Pubitemid 11151463)
25. Riemens S, van Tol A, Sluiter W, Dullaart RP 1998 Elevated plasma cholesteryl ester transfer in NIDDM: Relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein. Atherosclerosis 140:71-79 (Pubitemid 28378456)
26. Dullaart RP, Riemens SC, Scheek LM, Van Tol A 1999 Insulin decreases plasma cholesteryl ester transfer but not cholesterol esterification in healthy subjects as well as in normotriglyceridaemic patients with type 2 diabetes. Eur J Clin Invest 29:663-671 (Pubitemid 29366713)
27. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith Jr SC, Spertus JA, Costa F 2005 Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735-2752 (Pubitemid 41532612)
28. Channon KM, Clegg RJ, Bhatnagar D, Ishola M, Arrol S, Durrington PN 1990 Investigation of lipid transfer in human serum leading to the development of an isotopic method for the determination of endogenous cholesterol esterification and transfer. Atherosclerosis 80:217-226 (Pubitemid 20029792)
29. SutherlandWH,Walker RJ, Lewis-Barned NJ, Pratt H, TillmanHC 1994 Plasma cholesteryl ester transfer in patients with non-insulin dependent diabetes mellitus. Clin Chim Acta 231:29-38 (Pubitemid 24372389)
30. van Venrooij FV, Stolk RP, Banga JD, Sijmonsma TP, van Tol A, Erkelens DW, Dallinga-Thie GM; DALI Study Group 2003 Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Diabetes Care 26: 1216-1223 (Pubitemid 36929275)
31. Dullaart RP, De Vries R, Scheek L, Borggreve SE, Van Gent T, Dallinga-Thie GM, Ito M, Nagano M, Sluiter WJ, Hattori H, Van Tol A 2004 Type 2 diabetes mellitus is associated with differential effects on plasma cholesteryl ester transfer protein and phospholipid transfer protein activities and concentrations. Scand J Clin Lab Invest 64:205-215 (Pubitemid 38803104)
32. Glomset JA, Wright JL 1964 Some properties of a cholesterol esterifying enzyme in human plasma. Biochim Biophys Acta 89:266-276
33. Dullaart RP, Sluiter WJ, Dikkeschei LD, Hoogenberg K, Van Tol A 1994 Effect of adiposity on plasma lipid transfer protein activities: A possible link between insulin resistance and high density lipoprotein metabolism. Eur J Clin Invest 24:188-194 (Pubitemid 24197267)
34. Dullaart RP, Perton F, Kappelle PJ, de Vries R, Sluiter WJ, van Tol A 2010 Plasma lecithin:cholesterol acyltransferase activity modifies the inverse relationship of C-reactive protein with HDL cholesterol in nondiabetic men. Biochim Biophys Acta 1801:84-88
35. Albers JJ, Chen CH, Adolphson JL 1981 Lecithin:cholesterol acyltransferase (LCAT) mass; its relationship to LCAT activity and cholesterol esterification rate. J Lipid Res 22:1206-1213 (Pubitemid 12173297)
36. Florén CH, Chen CH, Franzén J, Albers JJ 1987 Lecithin:cholesterol acyltransferase in liver disease. Scand J Clin Lab invest 47:613-617
37. Mann CJ, Yen FT, Grant AM, Bihain BE 1991 Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest 88:2059-2066
38. Persson M, Hedblad B, Nelson JJ, Berglund G 2007 Elevated Lp- PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol 27:1411-1416 (Pubitemid 46823453)
39. Noto H, Chitkara P, Raskin P 2006 The role of lipoprotein-associated phospholipase A(2) in the metabolic syndrome and diabetes. J Diabetes Complications 20:343-348 (Pubitemid 44633698)
40. Lagrost L, Barter PJ 1992 Cholesteryl ester transfer protein promotes the association of HDL apolipoproteins A-I and A-II with LDL: Potentiation by oleic acid. Biochim Biophys Acta 1127:255-262
41. 2+-mediated oxidation of dialyzed plasma: Effects on low and high density lipoproteins and cholesteryl ester transfer protein. J Lipid Res 32:243-250
42. Wang J, Gu Q, Li K, Zhang C 2007 CETP and oxidized LDL levels increase in dyslipidemic subjects. Clin Biochem 40:995-999 (Pubitemid 47301799)
43. SuganoM,Sawada S, Tsuchida K, Makino N,KamadaM2000Low density lipoproteins develop resistance to oxidative modification due to inhibition of cholesteryl ester transfer protein by a monoclonal antibody. J Lipid Res 41:126-133 (Pubitemid 30051850)
44. Sánchez-Quesada JL, Benítez S, Pérez A, Wagner AM, Rigla M, Carreras G, Vila L, Camacho M, Arcelus R, Ordóñez-Llanos J 2005 The inflammatory properties of electronegative low-density lipoprotein from type 1 diabetic patients are related to increased plateletactivating factor acetylhydrolase activity. Diabetologia 48:2162-2169 (Pubitemid 41416930)
45. Chauffe RJ, Wilensky RL, Mohler 3rd ER 2010 Recent developments with lipoprotein-associated phospholipase A2 inhibitors. Curr Atheroscler Rep 12:43-47
46. White H 2010 Why inhibition of lipoprotein-associated phospholipase A2 has the potential to improve patient outcomes. Curr Opin Cardiol 25:299-301
47. Dullaart RP, Perton F, Van Der Klauw MM, Hillege HL, Sluiter WJ; PREVEND Study Group 2010 High plasma lecithin:cholesterol acyltransferase activity does not predict low incidence of cardiovascular events: Possible attenuation of cardioprotection associated with high HDL cholesterol. Atherosclerosis 208:537-542
48. Bruce C, Davidson WS, Kussie P, Lund-Katz S, Phillips MC, Ghosh R, TallAR1995 Molecular determinants of plasma cholesteryl ester transfer protein binding to high density lipoproteins. J Biol Chem 270:11532-11542